# Antibody recruiting molecules

## Overview
BHV-1100 (previously known as KP1237) is an antibody-recruiting molecule (ARM). ARMs bind to specific targets to facilitate antibody engagement, enhancing immune response against multiple myeloma.

### Therapeutics
- **Antibody recruiting molecules**  
  [BHV-1100](/content/therapeutics/antibody-recruiting-molecules/bhv-1100/index.html)  
- **Antibody therapy**  
  - [ALLO-647](/content/therapeutics/antibody-therapy/allo-647/index.html)  
  - [Anselamimab](/content/therapeutics/antibody-therapy/anselamimab/index.html)  
  - [AO-176](/content/therapeutics/antibody-therapy/ao-176/index.html)  
  - [Birtamimab](/content/therapeutics/antibody-therapy/birtamimab/index.html)  
  - [CAEL-101](/content/therapeutics/antibody-therapy/cael-101/index.html)  
  - [Daratumumab](/content/therapeutics/antibody-therapy/daratumumab/index.html)  
  - [Denosumab](/content/therapeutics/antibody-therapy/denosumab/index.html)  
  - [Elotuzumab](/content/therapeutics/antibody-therapy/elotuzumab/index.html)  
  - [Isatuximab](/content/therapeutics/antibody-therapy/isatuximab/index.html)  
  - [ISB 1342](/content/therapeutics/antibody-therapy/isb-1342/index.html)  
  - [ISB 1442](/content/therapeutics/antibody-therapy/isb-1442/index.html)  
  - [MOR202](/content/therapeutics/antibody-therapy/mor202/index.html)  
  - [TAK-079](/content/therapeutics/antibody-therapy/tak-079/index.html)

### Research & Development
The development of BHV-1100 and other ARM candidates is crucial for advancing treatment modalities in multiple myeloma. This tailored approach aims to leverage the body's immune system in innovative ways.

## References
For additional details on the therapeutic strategies and ongoing clinical studies, please review our full list of [all therapeutics](/content/therapeutics/index.html).